Initial results from the HALT-MS trial suggest that autologous hematopoietic stem cell transplantation may be a highly effective treatment for patients with aggressive relapsing-remitting MS. However, some worry that the aggressive therapy is needlessly risky when safer alternatives are available and may be just as effective.

A pair of studies in a Canadian multiple sclerosis cohort finds more evidence of early neurodegenerative biology and a potentially diagnostic autoimmune antibody increase in children with MS